



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/516,405	11/30/2004	Wolfgang Demmer	9013.0099	2828

Attn: Dennis E. Stenzel, Esq.
Chemoff, Vilhauer, McClung & Stenzel, LLP
Suite 1600
601 S.W. Second Avenue
Portland, OR 97204-3157

7590 08/03/2010

EXAMINER

FERNANDEZ, SUSAN EMILY

ART UNIT

PAPER NUMBER

1651

MAIL DATE

DELIVERY MODE

08/03/2010

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/516,405

Applicant(s)

DEMMER ET AL.

Examiner

SUSAN E. FERNANDEZ

Art Unit

1651

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 28 September 2009.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 11, 14 and 15 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 11, 14 and 15 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB-08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

The amendment filed September 28, 2009, has been received and entered.

Claims 1-10, 12, 13, and 16 are cancelled. Claims 11, 14, and 15 are pending and examined on the merits.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claim 11 is rejected under 35 U.S.C. 103(a) as being unpatentable over Zeng et al. (Ind. Eng. Chem. Res. 1998, 37: 159-165) in view of Langlotz et al. (Journal of Chromatography. 1992, 591: 107-113).

Zeng et al. points out that affinity membrane chromatography brings solute into close proximity to bound ligands through convective transport (page 159, first paragraph). Specifically, Zeng et al. discloses a membrane on which p-aminobenzamidine is immobilized (abstract). It is noted that "p-Aminobenzamidine (PAB) can serve as a ligand for trypsin and trypsin-like enzymes (such as urokinases, plasminogen activators, and serine proteases)" (page 160, first paragraph). A PAB-chitosan affinity membrane is obtained by first cross-linking a chitosan membrane, incorporating carboxyl groups in the cross-linked chitosan membrane by immersing the membrane in a succinic anhydride solution for 16 hours, blocking unreacted amino groups by using an acetic anhydride and methanol solution for 2 hours, removing residual acetic anhydride and succinic anhydride by NaOH immersion for 1 hour, and then coupling the PAB to the treated chitosan membrane (page 160, second column, first paragraph). Ten PAB-chitosan flat membranes were then sandwiched in a cartridge having four inlet ports and one outlet port (page 161, first full paragraph). The protein solution for treatment was loaded into the cartridge with a peristaltic pump (page 161, first full paragraph). Therefore, Zeng et al. teaches a device for removing proteases from biological and pharmaceutical solutions comprising a housing having a fluid inlet and a fluid outlet, said housing containing a plurality of membranes arranged therein in series.

The PAB-chitosan affinity membranes were used for adsorption of trypsin (page 164, first two paragraphs) and for purification of trypsin from a crude trypsin solution (page 164, first column, last paragraph through second column, second paragraph). It was concluded that the PAB-chitosan affinity membranes have "...high permeability, good mechanical properties,

chemical stability, and high ligand density” (page 165, last paragraph) and can be efficient for trypsin purification (abstract).

Zeng et al. does not expressly disclose that the PAB membranes for trypsin purification consist essentially of epoxy-functionalized microporous membranes each containing epoxy groups chemically coupled to PAB.

Langlotz discloses coupling protein to epoxy-activated membranes (page 107, second column, last paragraph). The studies were performed with Sartobind Epoxy, an epoxy-activated polymeric composite membrane (page 108, first column, third full paragraph) wherein protein solutions were circulated through the membranes for 2-26 hours (page 108, first column, last full paragraph). Proteins that were tested were protein A, rabbit IgG, and soybean trypsin inhibitor (page 108, first column, first full paragraph and page 109, second column) all of which coupled to the epoxy-activated membrane (page 109, second column).

At the time the invention was made, it would have been obvious to the person of ordinary skill in the art to have coupled the PAB to the epoxy-activated membrane of Langlotz et al. instead of a chitosan membrane when practicing the Zeng invention to create a device comprising PAB membranes for trypsin adsorption/purification. One of ordinary skill in the art would have been motivated to do this because it would have required fewer steps and less time in preparing each PAB membrane. Specifically, the chitosan membrane must undergo various pretreatment steps prior to coupling the PAB, according to Zeng et al. For pretreatment, the chitosan membrane is cross-linked, the carboxyl groups are incorporated in the cross-linked chitosan membrane by immersing the membrane in a succinic anhydride solution for 16 hours, the unreacted amino groups are blocked by using an acetic anhydride and methanol solution for 2

hours, and then the residual acetic anhydride and succinic anhydride are removed by NaOH immersion for 1 hour (page 160, second column, first paragraph). These pretreatment steps require a total of at least 19 hours. On the other hand, for binding a protein to the epoxy-activated membrane of Langlotz et al., the Sartobind Epoxy membrane does not need to be pretreated.

Furthermore, one of ordinary skill in the art would have been motivated to have made the substitution since Langlotz et al. recognizes that affinity membranes, such as a p-benzamidine membrane, can be used for removal of the proteases thrombin and kallikrein from blood (page 107, second column, first paragraph). Also, as the epoxy-activated membrane of Langlotz et al. can be coupled to various proteins, including a known protease inhibitor (soybean trypsin inhibitor), there would have been reasonable expectation of success in binding other proteins, including PAB. Thus, claim 11 is rendered obvious.

A holding of obviousness is clearly required.

Claims 1 and 10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hermanson et al. (Immobilized Affinity Ligand Techniques. 1992. Academic Press, Inc. San Diego, California) in view of Langlotz et al., Preece et al. (Journal of Biological Chemistry. 1996. 271(20): 11634-11640), and Zeng et al.

Hermanson et al. discloses that "for many biological studies it is essential to completely remove undesirable proteases from biological solutions" (page 355, last paragraph). Examples of affinity supports successfully used for this purpose include immobilized soybean trypsin inhibitor and immobilized p-aminobenzamidine (page 355, last paragraph). The use of

immobilized p-aminobenzamidine for protease removal (page 359, second-to-last paragraph) is by column chromatography (pages 318 and 319) as is the use of immobilized soybean trypsin inhibitor (pages 358 and 359).

Hermanson et al. does not expressly disclose that p-aminobenzamidine is immobilized on epoxy-functionalized microporous membranes containing epoxy groups chemically coupled to at least one protease inhibitor selected from the group consisting of p-aminobenzamidine, pepstatin, bestatin, diprotin, antipain, chymostatin, leupeptin (leupeptin), E64, and TLCK, wherein the membranes, each containing two different protease inhibitors, are arranged in series in a device comprising a housing having a fluid inlet and a fluid outlet.

Zeng et al. points out that compared to column chromatography, affinity membrane chromatography bring solute into close proximity to bound ligands through convective transport (page 159, first paragraph). Examples of biospecific ligands incorporated in micro- or macroporous membranes include trypsin inhibitors (page 159, first paragraph). Specifically, Zeng et al. discloses a membrane on which p-aminobenzamidine is immobilized (abstract). A PAB-chitosan affinity membrane is obtained by first cross-linking a chitosan membrane, incorporating carboxyl groups in the cross-linked chitosan membrane by immersing the membrane in a succinic anhydride solution for 16 hours, blocking unreacted amino groups by using an acetic anhydride and methanol solution for 2 hours, removing residual acetic anhydride and succinic anhydride by NaOH immersion for 1 hour, and then coupling the PAB to the treated chitosan membrane (page 160, second column, first paragraph). Ten PAB-chitosan flat membranes were sandwiched in a cartridge having four inlet ports and one outlet port (page 161, first full paragraph). The protein solution for treatment was loaded into the cartridge with a

peristaltic pump (page 161, first full paragraph). Therefore, Zeng et al. teaches a device for removing proteases from biological and pharmaceutical solutions comprising a housing having a fluid inlet and a fluid outlet, said housing containing a plurality of membranes arranged therein in series. Zeng et al. demonstrated that the device is efficient for trypsin purification (abstract).

Langlotz et al. discloses coupling protein to epoxy-activated membranes (page 107, second column, last paragraph). The studies were performed with Sartobind Epoxy, an epoxy-activated polymeric composite membrane (page 108, first column, third full paragraph) wherein protein solutions were circulated through the membranes for 2-26 hours (page 108, first column, last full paragraph). Proteins that were tested were protein A, rabbit IgG, and soybean trypsin inhibitor (page 108, first column, first full paragraph and page 109, second column) all of which coupled to the epoxy-activated membrane (page 109, second column).

Preece et al. discloses that pepstatin, bestatin, diprotin, antipain, chymostatin, leupeptin (leupeptin), E64, and TLCK are serine protease inhibitors (page 11635, second column, first paragraph and page 11637, first column, first full paragraph).

At the time the invention was made, it would have been obvious to the person of ordinary skill in the art to have removed proteases from fluids with the device of Zeng et al. wherein instead of PAB-chitosan flat membranes, the device comprises epoxy-activated membranes each comprising two different protease inhibitors selected from p-aminobenzamidine, pepstatin, bestatin, diprotin, antipain, chymostatin, leupeptin (leupeptin), E64, and TLCK. One of ordinary skill in the art would have been motivated to do this since, compared to column chromatography, affinity membrane chromatography bring solute into close proximity to bound ligands through convective transport. Moreover, Zeng et al. demonstrates that a membrane comprising

immobilized p-aminobenzamidine is suitable for binding to trypsin. It would have been advantageous to have bound the protease inhibitors to the epoxy-activated membranes of Langlotz et al. rather than the membrane of Zeng et al. as fewer steps and less time would have been required in binding the protease inhibitors to the membranes. There would have been reasonable expectation of success in immobilizing at least one of the protease inhibitors listed above since the epoxy-activated membrane of Langlotz et al. is shown to be suitable for binding to proteins in general. Moreover, there would have been a reasonable expectation of success in removing proteases with any of the protease inhibitors listed as two immobilized protease inhibitors (p-aminobenzamidine and soybean trypsin inhibitor) are suitable for removal of proteases (Hermanson).

Finally, it would have been obvious to have bound two or more different protease inhibitors to the epoxy-activated membrane since it would have reduced the concentration of a variety of proteases in a biological solution.

Given that the membrane is epoxy-activated and is the same membrane used in the claimed invention (Sartobind Epoxy, page 5, lines 16-17), the epoxy groups on the membrane are indeed chemically coupled by a chemical bond to the protease inhibitor(s). Thus, claims 11, 14, and 15 are rendered obvious.

A holding of obviousness is clearly required.

Response to Arguments

Applicant's arguments filed September 28, 2009, have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made in view of Zeng et al., Langlotz et al., and Hermanson et al.

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUSAN E. FERNANDEZ whose telephone number is (571)272-3444. The examiner can normally be reached on Mon-Fri 8:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Wityshyn can be reached on (571) 272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Leon B Lankford/

Susan E. Fernandez

Application/Control Number: 10/516,405

Page 10

Art Unit: 1651

Primary Examiner, Art Unit 1651

Examiner
Art Unit 1651

sef